Home Companies Catalysts Deep Dives

Prostate cancer

PC · Oncology · 7 drugs · 9 indications

Cancer of the prostate gland. Includes hormone-sensitive and castration-resistant disease.
Competitive Landscape (7 drugs)
DrugCompanyMechanismModalityRouteStage
saruparibAZNPARP1 selective inhibitorSmall moleculeORALPHASE3
Ifinatamab deruxtecanDSNKY, AZNB7-H3-directed (DXd payload)ADCIVPHASE3
225Ac-PSMA-617NVSPSMA-targetingRadioligand therapyIVPHASE3
XaluritamigAMGNSTEAP1-targeting BiTE (bispecific T-cell engager)Bispecific T-cell engager (BiTE)IV/SCPHASE3
PluvictoNVSPSMA-targetingRadioligand therapyIVAPPROVED
LynparzaAZN, MRKPARP inhibitorSmall moleculeORALAPPROVED
XtandiALPMYAndrogen receptor inhibitorSmall moleculePOAPPROVED
Indications (9)
mCRPC
Xtandi APPROVED
Metastatic CRPC
Xaluritamig PHASE3
nmCRPC
Xtandi APPROVED
mHSPC
Xtandi APPROVED
Metastatic castration-resistant prostate cancer
saruparib PHASE2Ifinatamab deruxtecan PHASE3
Metastatic castration-resistant prostate cancer (HRR-mutated)
Lynparza APPROVED
PSMA-positive mCRPC
Pluvicto APPROVED
PSMA-positive mHSPC
Pluvicto FILED
mCRPC (post-Lu-PSMA or treatment-naive)
225Ac-PSMA-617 PHASE3
Upcoming Catalysts
Pluvicto - Pre-Chemo mCRPC - FDA ApprovalREGULATORY
NVSQ1 2026
I-DXd - SCLC - Ph3 - Clinical Hold Update (IDeate-Lung02)CLINICAL
DSNKY2026
225Ac-PSMA-617 - mCRPC - Ph3 - StartCLINICAL
NVS2026
XTANDI - US Patent Expiration PreparationCOMPETITIVE
ALPMYUS: 2027
Data from Supabase · Updated 2026-03-24